Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kyorin Pharmaceutical Co's annualized net income for the quarter that ended in Mar. 2026 was 円-2,684 Mil. Kyorin Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円136,482 Mil. Therefore, Kyorin Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -1.97%.
The historical rank and industry rank for Kyorin Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:4569'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.56 Med: 4.57 Max: 7.07
Current: 2.58
During the past 13 years, Kyorin Pharmaceutical Co's highest Return-on-Tangible-Equity was 7.07%. The lowest was 2.56%. And the median was 4.57%.
TSE:4569's Return-on-Tangible-Equity is ranked worse than 65.41% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs TSE:4569: 2.58
Kyorin Pharmaceutical Co (TSE:4569) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Kyorin Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Kyorin Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Kyorin Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Return-on-Tangible-Equity Chart
TSE:4569 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -1.97% mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Return-on-Tangible-Equity of -1.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kyorin Pharmaceutical Co and its competitors. Over the past decade, Kyorin Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 2.56 to 7.07. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #588 out of 899 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Kyorin Pharmaceutical Co's Return-on-Tangible-Equity too high?
Kyorin Pharmaceutical Co's current Return-on-Tangible-Equity is -1.97%. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 7.07. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #588 out of 899 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #588 out of 899 companies for Return-on-Tangible-Equity. This places Kyorin Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.95. Historically, Kyorin Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 2.56 to 7.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Return-on-Tangible-Equity is -1.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,583.07, compared to a current price of 円1,170.00 — trading 26.1% below its estimated fair value. The current Return-on-Tangible-Equity is -1.97%. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Return-on-Tangible-Equity is -1.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,170.00 is trading 26.1% below its estimated GF Value™ of 円1,583.07.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Return-on-Tangible-Equity: -1.97%
GF Value™: 円1,583.07 vs. price of 円1,170.00 (26.1% below fair value)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
